To report the preliminary data on the safety and efficacy of MRI-based thrombolysis in UnCLOS patients.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
- Urokinase (Abbokinase®)Drug
Intervention Desc: Thrombolytic agent
Retrospective data analysis
Subjects received thrombolysis with IV tPA or combined IV tPA and IA urokinase within 3 hours of onset or IA urokinase within 6 hours from symptom detection. Rates of immediate and 5-day recanalization, early neurological improvement and symptomatic intracranial hemorrhage within 48 h after treatment and 3-month mRS were compared between patients with UnCLOS and those with clear-onset stroke (CLSO).
|Type||Measure||Time Frame||Safety Issue|
|No outcomes associated with this trial.|